Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients

被引:13
作者
Artan, R [1 ]
Akcam, M [1 ]
Yilmaz, A [1 ]
Kocacik, D [1 ]
机构
[1] Akdeniz Univ, Fac Med, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, TR-07059 Antalya, Turkey
关键词
interferon; HCV; chronic hepatitis; hemodialysis; thalassemia;
D O I
10.1179/joc.2005.17.6.651
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We assessed the effectiveness of interferon (IFN) monotherapy in thalassemic or hemodialysis patients with chronic hepatitis C viral (HCV) infection. Ten thalassemic and four hemodialysis patients were included in the study. Chronic HCV was confirmed with both serum HCV-RNA and liver histopathology. IFN alpha-2a was administered three times a week for 24-48 weeks, at a dose of 5 MU/m(2) (Maximum 6 million units). Sustained response was defined as negative HCV-RNA at least 24 weeks after termination of the treatment. All patients completed the study. Eight of 10 thalassemic (80%) and one of four hemodialysis patients (25%) showed a sustained response. IFN monotherapy proved to be an effective treatment, especially in thalassemic patients with chronic HCV. IFN monotherapy seems reasonable for patients with thalassemia and chronic hepatitis C virus in whom ribavirin cannot be used.
引用
收藏
页码:651 / 655
页数:5
相关论文
共 18 条
[1]  
Di Ciommo V, 2003, J VIRAL HEPATITIS, V10, P210, DOI 10.1046/j.1365-2893.2003.00420.x
[2]  
DiMarco V, 1997, BLOOD, V90, P2207
[3]  
Ebeling F, 2001, AM J GASTROENTEROL, V96, P1237, DOI 10.1111/j.1572-0241.2001.03631.x
[4]  
GONZALEZPERALTA RG, 2004, PEDIAT GASTROINTESTI, P1156
[5]   Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT [J].
Jacobson, IM ;
Ahmed, F ;
Russo, MW ;
Lebovics, E ;
Dieterich, DI ;
Esposito, SP ;
Bach, N ;
Klion, F ;
Tobias, H ;
Antignano, L ;
Brown, RS ;
Gabbaizadeh, D ;
Geders, J ;
Levendoglu, H .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (09) :1700-1705
[6]   Treatment of acute hepatitis C with interferon alfa-2b [J].
Jaeckel, E ;
Cornberg, M ;
Wedemeyer, H ;
Santantonio, T ;
Mayer, J ;
Zankel, M ;
Pastore, G ;
Dietrich, M ;
Trautwein, C ;
Manns, MP .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (20) :1452-1457
[7]  
Kamar N, 2003, NEPHROLOGIE, V24, P133
[8]   FORMULATION AND APPLICATION OF A NUMERICAL SCORING SYSTEM FOR ASSESSING HISTOLOGICAL ACTIVITY IN ASYMPTOMATIC CHRONIC ACTIVE HEPATITIS [J].
KNODELL, RG ;
ISHAK, KG ;
BLACK, WC ;
CHEN, TS ;
CRAIG, R ;
KAPLOWITZ, N ;
KIERNAN, TW ;
WOLLMAN, J .
HEPATOLOGY, 1981, 1 (05) :431-435
[9]   Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major [J].
Li, CK ;
Chan, PKS ;
Ling, SC ;
Ha, SY .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (03) :755-758
[10]   Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment [J].
Mamori, S ;
Suzuki, F ;
Hosaka, T ;
Akuta, N ;
Someya, T ;
Kobayashi, M ;
Tsubota, A ;
Suzuki, Y ;
Saitoh, S ;
Arase, Y ;
Ikeda, K ;
Kumada, H .
JOURNAL OF GASTROENTEROLOGY, 2004, 39 (08) :776-782